Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 6/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30682049 | 0.87 | CCR5 (0.56) | SMN1; SMN2SLC6A4SMPD1ALDH1A1MAPK1 | |
| SCHEMBL1447864 | 0.85 | SLC6A4 (0.59) | SMN1; SMN2SLC6A4SMPD1ALDH1A1CYP1A2 | |
| SCHEMBL30504080 | 0.85 | SLC6A4 (0.59) | SMN1; SMN2SLC6A4SMPD1ALDH1A1CYP1A2 | |
| SCHEMBL25180595 | 0.82 | CCR5 (0.57) | SLC6A4SMPD1CCR5MAOBNPC1 | |
| SCHEMBL13929725 | 0.82 | ACHE (0.55) | SMN1; SMN2ALDH1A1CYP1A2CYP3A4MAPT | |
| SCHEMBL17441250 | 0.81 | SMPD1 (0.57) | SMN1; SMN2SMPD1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL743015 | 0.81 | APP (0.61) | SMN1; SMN2ALDH1A1CYP1A2CYP3A4MAPT | |
| SCHEMBL4572874 | 0.79 | KDM4E (0.59) | SMN1; SMN2ALDH1A1MAPTMAPK1HPGD | |
| SCHEMBL9217221 | 0.79 | ALDH1A1 (0.52) | SMN1; SMN2SLC6A4ALDH1A1MAOB | |
| SCHEMBL23643207 | 0.79 | CSF1R (0.55) | SMN1; SMN2ALDH1A1CYP1A2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765739-B2 | Azetidine compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765739-B2 | Azetidine compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-2431365-A1 | AZETIDINE COMPOUND AND MEDICINAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20100331301-A1 | AZETIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331301-A1 | AZETIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331301-A1 | AZETIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| WO-2010131738-A1 | AZETIDINE COMPOUND AND MEDICINAL USE THEREOF | 日本たばこ産業株式会社 (JP) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331301-A1 | AZETIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP2C9, QDPR | SMN1; SMN2 1874/4885SLC6A4 136/4885SMPD1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.